1. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471, 2007
2. Psaty BM, Furberg CD: Rosiglitazone and cardiovascular risk. N Engl J Med 356:2522–2524, 2007
3. Saul S: Heart attack risk seen in drug for diabetes [article online], 22 May 2007. New York Times. Available from http://www.nytimes.com/2007/05/22/business/22drug.html. Accessed 22 June 2007
4. National Heart, Lung, and Blood Institute: Questions and answers: use of rosiglitazone (Avandia) in the National Heart, Lung, and Blood Institute's Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) and Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trials [article online],2007. Available from http://www.nhlbi.nih.gov/new/press/07-rosi-qa.htm. Accessed 11 July 2007
5. The Endocrine Society: The Endocrine Society statement to providers on the report published in the New England Journal of Medicine on Avandia [article online], 2007. Available from http://www.endo-society.org/publicpolicy/policy/avandia.cfm. Accessed 11 July 2007